PMID- 25083080
OWN - NLM
STAT- MEDLINE
DCOM- 20150417
LR  - 20220321
IS  - 2219-2840 (Electronic)
IS  - 1007-9327 (Print)
IS  - 1007-9327 (Linking)
VI  - 20
IP  - 27
DP  - 2014 Jul 21
TI  - Non-alcoholic fatty liver disease and type 2 diabetes mellitus: the liver disease 
      of our age?
PG  - 9072-89
LID - 10.3748/wjg.v20.i27.9072 [doi]
AB  - Non-alcoholic fatty liver disease (NAFLD) is a chronic liver disease that might 
      affect up to one-third of the adult population in industrialised countries. NAFLD 
      incorporates histologically and clinically different non-alcoholic entities; 
      fatty liver (NAFL, steatosis hepatis) and steatohepatitis (NASH-characterised by 
      hepatocyte ballooning and lobular inflammation +/- fibrosis) might progress to 
      cirrhosis and rarely to hepatocellular cancer. NAFL increasingly affects children 
      (paediatric prevalence is 4.2%-9.6%). Type 2 diabetes mellitus (T2DM), insulin 
      resistance (IR), obesity, metabolic syndrome and NAFLD are particularly closely 
      related. Increased hepatic lipid storage is an early abnormality in insulin 
      resistant women with a history of gestational diabetes mellitus. The accumulation 
      of triacylglycerols in hepatocytes is predominantly derived from the plasma 
      nonesterified fatty acid pool supplied largely by the adipose tissue. A few NAFLD 
      susceptibility gene variants are associated with progressive liver disease, IR, 
      T2DM and a higher risk for hepatocellular carcinoma. Although not approved, 
      pharmacological approaches might be considered in NASH patients.
FAU - Firneisz, Gabor
AU  - Firneisz G
AD  - Gabor Firneisz, 2 Department of Internal Medicine, Semmelweis University, H-1088 
      Budapest, Hungary.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - World J Gastroenterol
JT  - World journal of gastroenterology
JID - 100883448
RN  - 0 (Dipeptidyl-Peptidase IV Inhibitors)
RN  - 0 (Fatty Acids, Nonesterified)
RN  - 0 (Inflammation Mediators)
RN  - 0 (Membrane Proteins)
RN  - 0 (Triglycerides)
RN  - EC 2.3.1.20 (DGAT2 protein, human)
RN  - EC 2.3.1.20 (Diacylglycerol O-Acyltransferase)
RN  - EC 3.1.1.3 (Lipase)
RN  - EC 3.1.1.3 (adiponutrin, human)
SB  - IM
MH  - Adiposity
MH  - Animals
MH  - Diabetes Mellitus, Type 2/diagnosis/*epidemiology/genetics/metabolism/therapy
MH  - Diacylglycerol O-Acyltransferase/metabolism
MH  - Diagnostic Imaging/methods
MH  - Dipeptidyl-Peptidase IV Inhibitors/therapeutic use
MH  - Fatty Acids, Nonesterified/metabolism
MH  - Genetic Predisposition to Disease
MH  - Humans
MH  - Inflammation Mediators/metabolism
MH  - Insulin Resistance
MH  - Lipase/genetics/metabolism
MH  - Liver/*metabolism/pathology
MH  - Liver Cirrhosis/epidemiology/metabolism
MH  - Membrane Proteins/genetics/metabolism
MH  - Mitochondria, Liver/metabolism
MH  - Non-alcoholic Fatty Liver 
      Disease/diagnosis/*epidemiology/genetics/metabolism/therapy
MH  - Predictive Value of Tests
MH  - Prevalence
MH  - Proton Magnetic Resonance Spectroscopy
MH  - Risk Factors
MH  - Triglycerides/metabolism
PMC - PMC4112878
OTO - NOTNLM
OT  - Dysfunctional adipose tissue
OT  - Genetics
OT  - Hepatocellular cancer
OT  - Insulin resistance
OT  - Liver cirrhosis
OT  - Non-alcoholic fatty liver disease
OT  - Non-alcoholic steatohepatitis
OT  - Obesity
OT  - Therapy
OT  - Type 2 diabetes mellitus
EDAT- 2014/08/02 06:00
MHDA- 2015/04/18 06:00
PMCR- 2014/07/21
CRDT- 2014/08/02 06:00
PHST- 2013/11/14 00:00 [received]
PHST- 2014/03/20 00:00 [revised]
PHST- 2014/05/12 00:00 [accepted]
PHST- 2014/08/02 06:00 [entrez]
PHST- 2014/08/02 06:00 [pubmed]
PHST- 2015/04/18 06:00 [medline]
PHST- 2014/07/21 00:00 [pmc-release]
AID - 10.3748/wjg.v20.i27.9072 [doi]
PST - ppublish
SO  - World J Gastroenterol. 2014 Jul 21;20(27):9072-89. doi: 10.3748/wjg.v20.i27.9072.